December 13, 2021
Study shows positive results for Roche’s Hemlibra in people with moderate or mild haemophilia A
Roche interim analysis of the phase III HAVEN 6 study, which show Hemlibra (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.